- ￥1919 - 13663
- TargetMol
- USA
- T2691
- 2025年07月13日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 保存条件：
RT
- 保质期：
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -2709℃ for several months.
- 英文名：
Oritavancin diphosphate
- 库存：
详询
- 供应商：
详询
- CAS号：
192564-14-0
- 规格：
2mg/5mg/10mg/25mg/50mg/1ml/10mM
| 规格： | 2mg | 产品价格： | ￥1919.0 |
|---|---|---|---|
| 规格： | 5mg | 产品价格： | ￥3130.0 |
| 规格： | 10mg | 产品价格： | ￥4741.0 |
| 规格： | 25mg | 产品价格： | ￥7794.0 |
| 规格： | 50mg | 产品价格： | ￥13663.0 |
| 规格： | 1ml/10mM | 产品价格： | ￥3232.0 |
ID：T2691
PURITY：99%+
Formula：C86H103Cl3N10O34P2
MolWt：1989.09
Appearance：白色粉末
Solubility：G410 mM in water
Bioactivity：Oritavancin diphosphate is a novel semisynthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive bacterial infections.
Status：
Pathways：Microbiology & Virology
Target：Antibacterial
Receptor：Others
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验Treatment of Infections Caused by Resistant Staphylococcus aureus
-positive organisms at an advanced stage of clinical testing: ceptobiprole and three new glycopeptides with potent bactericidal activity, oritavancin, dalbavancin, and telavancin. Thus, there are currently many effective drugs to treat resistant S. aureus
Treatment of Infections Due to Resistant Staphylococcus aureus
with broad-spectrum activity against Gm-positive organisms that have reached the phase II and III stages of clinical testing that will hopefully be approved for clinical use in the upcoming years: oritavancin, dalbavancin, omadacycline, tedizolid
技术资料暂无技术资料 索取技术资料
